The signature event in Cambridge Healthtech Institute’s Biomarker Series, the Ninth Annual Biomarkers & Diagnostics World Congress 2013 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-- making the Congress a perfect meeting place to share experiences, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its ninth year, the Biomarkers & Diagnostics World Congress is the leading annual meeting dedicated to biomarker and diagnostics research and implementation that consistently delivers a cutting-edge agenda, 400+ senior delegates, and a sold-out exhibit hall.

The program is expanded this year to include cutting-edge coverage of diagnostics, including clinical assay development, companion diagnostics, regulatory compliance, tissue diagnostics, and exosome biomarkers. The World Congress will continue offering a comprehensive coverage of biomarkers in drug development, including translational biomarkers, patient selection, drug-diagnostic co-development, and cancer drug resistance. The two Executive Summits are designed to bring together the drug development and diagnostics leaders to brainstorm strategies for Rx-Dx co-development.